Health economic analyses of secondary vaccine effects: a systematic review and policy insights

References

• Shulman J, Ahsan R, O’Malley K, 2021. Understanding global vaccine economics and research and development. [cited 2021 Jun 21]. Available from: https://www.sabinaspengroup.org/app/uploads/2021/01/sabin-aspen-report-2021-shulman-3.pdf
   Google Scholar
• Roush SW, Murphy, TV, The Vaccine-Preventable Disease Table Working Group, et al. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA. 2007;298(18):2155–2163.
   PubMed Web of Science ®Google Scholar
• Zhou F, Shefer A, Wenger J, et al. Economic evaluation of the routine childhood immunization program in the United States, 2009. Pediatrics. 2014;133(4):577–585.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Orenstein WA, Hinman AR. An opportunity to incentivize innovation to increase vaccine safety in the United States by improving vaccine delivery using vaccine patches. Vaccine. 2020;38(25):4060–4065.
   PubMed Web of Science ®Google Scholar
• UNICEF. 2021. Vaccines UNICEF supply division. [cited 2021 Sep 9]. Available from: https://www.unicef.org/supply/vaccines
   Google Scholar
• Pan American Health Organization. 2021. PAHO revolving fund. [cited 2021 Sep 9]. Available from: https://www.paho.org/en/revolvingfund
   Google Scholar
• Taylor P, 2011. Dutch government sells off vaccine facility. [cited 2021 Sep 9]. Available from: http://www.pharmafile.com/news/149629/netherlands-vaccine-institute-bilthoven-sale
   Google Scholar
• Baylor NW. The regulatory evaluation of vaccines for human use. Methods Mol Biol. 2016;1404:773–787.
   PubMedGoogle Scholar
• Watson M, Faron de Goër E. Are good intentions putting the vaccination ecosystem at risk? Hum Vaccin Immunother. 2016;12(9):2469–2474.
   PubMed Web of Science ®Google Scholar
• Francis DP. Successes and failures: Worldwide vaccine development and application. Biologicals. 2010;38(5):523–528.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. 2021. Vaccines licensed for use in the United States. [cited 2021 Sep 9]. Available from: https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-United-States
   Google Scholar
• World Health Organization. 2021. [cited 2021 Sep 9]. List of prequalified vaccines. Available from: https://extranet.who.int/pqweb/vaccines/list-prequalified-vaccines
   Google Scholar
• Centers for Disease Control and Prevention. Update: vaccine side effects, adverse reaction, contraindications, and precautions – recommendation of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 1996;45(RR–12):1–35.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention, 2021. ACIP vaccine recommendations and guidelines. [Cited 2021 Sep 9]. Available from: https://www.cdc.gov/vaccines/hcp/acip-recs/index.html
   Google Scholar
• World Health Organization, 2021. WHO vaccine position papers. [cited 2021 Sep 9]. Available from: https://www.who.int/teams/immunization-vaccines-and-biologicals/policies/position-papers
   Google Scholar
• Kroger A, Bahta L, Hunter P. 2021. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP), updated 4 May 2021. [cited 2021 Jun 21. Available from: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html
   Google Scholar
• Naylor A, Kauppi D, Schonfeld J. Therapeutic drug repurposing, repositioning and rescue part II: business review. Drug Discovery World.2015 (Spring) .57–72. .
   Google Scholar
• Fuge O, Vasdev N, Allchorne P et al, et al. Immunotherapy for bladder cancer. Res Rep Urol. 2015;7:65–79.
   PubMed Web of Science ®Google Scholar
• Zhand S, Hosseini SM, Tabarraei A, et al. Oral poliovirus vaccine-induced programmed cell death involves both intrinsic and extrinsic pathways in human colorectal cancer cells. Oncolytic Virother. 2018;7:95–105.
   PubMed Web of Science ®Google Scholar
• Chakraborty C, Sharma AR, Bhattacharya M, et al. Ongoing clinical trials of vaccines to fight against COVID-19 pandemic. Immune Netw. 2021;21(1):e5.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Kalkowsa DA, Badizadegan K. A health economic analysis for oral poliovirus vaccine to prevent COVID-19 in the United States. Risk Anal. 2021;41(2):376–386.
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2019. WHO guide for standardization of economic evaluations of immunization programmes, Edition II, October 2019. Initiative for Vaccine Research, Department of Immunization, Vaccine, and Biologicals: Geneva.
   Google Scholar
• Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat Med. 1999;18(23):3263–3282.
   PubMed Web of Science ®Google Scholar
• Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). Health Econ. 2001;10(8):751–774.
   PubMed Web of Science ®Google Scholar
• Bos JM, Alphen L, Postma MJ. The use of modeling in the economic evaluation of vaccines. Expert Rev Pharmacoecon Outcomes Res. 2002;2(5):443–455.
   PubMedGoogle Scholar
• Silver MC, Neumann PJ, Ma S, et al. Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines. Vaccine. 2021;39(46):6727–6734.
   PubMed Web of Science ®Google Scholar
• Nymark L, Vassall A. A comprehensive framework for considering additional unintended consequences in economic evaluation. Cost Eff Resour Alloc. 2020;18(1):27.
   PubMed Web of Science ®Google Scholar
• Scarbrough Lefebvre CD, Terlinden A, Standaert B. Dissecting the indirect effects caused by vaccines into the basic elements. Hum Vaccin Immunother. 2015;11(9):2142–2157.
   PubMed Web of Science ®Google Scholar
• Nymark LS, Sharma T, Miller A, et al. Inclusion of the value of herd immunity in economic evaluations of vaccines. A systematic review of methods used. Vaccine. 2017;35(49 Pt B):6828–6841.
   PubMed Web of Science ®Google Scholar
• Andrews JR, Baker S, Marks F, et al. Typhoid conjugate vaccines: a new tool in the fight against antimicrobial resistance. Lancet Infect Dis. 2019;19(1):e26–e30.
   PubMed Web of Science ®Google Scholar
• Joffe AM, Park E-C, Augustine A, et al. NIAID workshop on secondary vaccine effects. Nat Immunol. 2021;22(11):1363–1366.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Soares-Weiser K, López-López JA, et al. Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. BMJ. 2016;355:i5170.
   PubMed Web of Science ®Google Scholar
• Poland GA, Ovsyannikova IG, Kennedy RB. Personalized vaccinology: a review. Vaccine. 2018;36(36):5350–5357.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Suspension of rotavirus vaccine after reports of intussusception–United States, 1999. MMWR Morb Mortal Wkly Rep. 2004;53(34):786–789.
   PubMedGoogle Scholar
• Munoz FM, Cramer JP, Dekker CL, et al. Vaccine-associated enhanced disease: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2021;39(22):3053–3066.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Pallansch MA, Kew OM, et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal. 2006;26(6):1471–1505.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Duintjer Tebbens RJ. Retrospective cost-effectiveness analyses for polio vaccination in the United States. Risk Anal. 2006;26(6):1423–1440.
   PubMed Web of Science ®Google Scholar
• Council for International Organizations of Medical Sciences/World Health OrganizationDefinition and application of terms for vaccine pharmacovilance. [cited 2012 9 Sep]. Available from: https://cioms.ch/wp-content/uploads/2017/01/report_working_group_on_vaccine_LR.pdf
   Google Scholar
• World Health Organization, Causality assessment of an adverse event following immunization (‎AEFI)‎: user manual for the revised WHO classification, 2nd ed., 2019 update. [cited 2021 9 Sep]. Available from: 2019 https://www.who.int/publications/i/item/causality-assessment-aefi-user-manual-2019
   Google Scholar
• World Health Organization, 2019. Non-specific effects of vaccines: questions and answers. [cited 2021 Sep 9]. Available from: https://www.who.int/immunization/research/implementation/NSE_questions_answers_March2019.pdf
   Google Scholar
• Management Sciences for Health and World Health Organization. 2007. Drug and therapeutics committee training course. [cited 2021 Sep 9]. Available from: https://www.who.int/medicines/technical_briefing/tbs/Participant-s-Guide-All-Sessions.pdf
   Google Scholar
• Food and Drug Administration, 2021. Finding and learning about side effects (adverse reactions). [cited 2021 Sep 9]. Available from: https://www.fda.gov/drugs/information-consumers-and-patients-drugs/finding-and-learning-about-side-effects-adverse-reactions
   Google Scholar
• World Health Organization. 2013. Vaccine safety basics learning manual. [cited 2021 Sep 9]. Available from: http://vaccine-safety-training.org/tl_files/vs/pdf/vsb-manual.zip
   Google Scholar
• World Health Organization. 1972. International drug monitoring: the role of national centres, technical report series 498. [cited 2021 Sep 9]. Available from: https://www.who-umc.org/media/2680/who-technical-report-498.pdf
   Google Scholar
• Centers for Disease Control and Prevention. 2021. Preventing and managing adverse reactions. [cited 2021 Sep 9]. Available from: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/adverse-reactions.html
   Google Scholar
• Centers for Disease Control and Prevention. 2021. Understanding adverse events and side effects. [cited 2021 Sep 9]. Available from: https://www.cdc.gov/vaccinesafety/ensuringsafety/sideeffects/index.html.
   Google Scholar
• Code of Federal Regulations. 2020. Title 21 - food and drugs chapter 1 - Food and drug administration department of health and human services subchapter D - drugs for human use. [cited 2021 Sep 9]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=312.32
   Google Scholar
• Cousins S. Contaminated vaccine deaths a serious setback for Syria. Lancet. 2014;384(9949):1172.
   PubMed Web of Science ®Google Scholar
• Fortin J. 2017. Mishandled measles vaccine kills 15 children in South Sudan. [cited 2017 Jun 2]. Available from: https://www.nytimes.com/2017/06/02/international-home/vaccines-south-sudan.html
   Google Scholar
• Atanasoff S, Ryan T, Lightfoot R, et al. Shoulder injury related to vaccine administration (SIRVA). Vaccine. 2010;28(51):8049–8052.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Orenstein WA, Hinman AR. Performance of the United States Vaccine Injury Compensation Program (VICP): 1988-2019. Vaccine. 2020;38(9):2136–2143.
   PubMed Web of Science ®Google Scholar
• Kandasamy R, Voysey M, McQuaid F, et al. Non-specific immunological effects of selected routine childhood immunisations: systematic review. BMJ. 2016;355:i5225.
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2014. Evidence based recommendations on non-specific effects of BCG, DTP-containing and measles-containing vaccines on mortality in children under 5 years of age. [cited 2021 Sep 9]. Available from: https://www.who.int/immunization/sage/meetings/2014/april/1_NSE_Backgroundpaper_final.pdf?ua=1
   Google Scholar
• Conklin L, Hviid A, Orenstein WA, et al. Vaccine safety issues at the turn of the 21st century. BMJ Glob Health. 2021;6(Suppl 2):e004898.
   PubMed Web of Science ®Google Scholar
• Taylor B, Miller E, Farrington C, et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet. 1999;353(9169):2026–2029.
   PubMed Web of Science ®Google Scholar
• Jain A, Marshall J, Buikema A, et al. Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. JAMA. 2015;313(15):1534–1540.
   PubMed Web of Science ®Google Scholar
• Miller E, Andrews N, Waight P et al, et al. Bacterial infections, immune overload, and MMR vaccine. Measles, mumps, and rubella. Arch Dis Child. 2003;88(3):222–223.
   PubMed Web of Science ®Google Scholar
• Stowe J, Andrews N, Taylor B, et al. No evidence of an increase of bacterial and viral infections following measles, mumps and rubella vaccine. Vaccine. 2009;27(9):1422–1425.
   PubMed Web of Science ®Google Scholar
• Andrews N, Stowe J, Thomas SL, et al. The risk of non-specific hospitalised infections following MMR vaccination given with and without inactivated vaccines in the second year of life. Comparative self-controlled case-series study in England. Vaccine. 2019;37(36):5211–5217.
   PubMed Web of Science ®Google Scholar
• Tielemans S, de Melker HE, Hahné SJM, et al. Non-specific effects of measles, mumps, and rubella (MMR) vaccination in high income setting: population based cohort study in the Netherlands. BMJ. 2017;358:j3862.
   PubMed Web of Science ®Google Scholar
• Watts RD, Li IW. Use of checklists in reviews of health economic evaluations, 2010 to 2018. Value Health. 2019;22(3):377–382.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Odahowski CL. The costs and valuation of health impacts of measles and rubella risk management policies. Risk Anal. 2016;36(7):1357–1382.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Kalkowska DA. Potential future use, costs, and value of poliovirus vaccines. Risk Anal. 2021;41(2):349–363.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Badizadegan ND. Modeling the transmission of measles and rubella to support global management policy analyses and eradication investment cases. Risk Anal. 2017;37(6):1109–1131.
   PubMed Web of Science ®Google Scholar
• Nymark LS, Miller A, Vassall A. Inclusion of additional unintended consequences in economic evaluation: a systematic review of immunization and tuberculosis cost-effectiveness analyses. Pharmacoecon Open. 2021;5(1):1–17.
   PubMedGoogle Scholar
• Fens T, de Boer PT, van Puijenbroek EP, et al. Inclusion of safety-related issues in economic evaluations for seasonal influenza vaccines: a systematic review. Vaccines (Basel). 2021;9(2):111.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Kalkowska DA. Review of poliovirus modeling performed from 2000-2019 to support global polio eradication. Expert Rev Vaccines. 2020;19(7):661–686.
   PubMed Web of Science ®Google Scholar
• Miller MA, Sutter RW, Strebel PM et al, et al. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. JAMA. 1996;276(12):967–971.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Duintjer Tebbens RJ. Eradication versus control for poliomyelitis: an economic analysis. Lancet. 2007;369(9570):1363–1371.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Pallansch MA, Kew OM et al, et al. Uncertainty and sensitivity analyses of a decision analytic model for post-eradication polio risk management. Risk Anal. 2008;28(4):855–876.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Tebbens RJD, Pallansch MA, et al. The risks, costs, and benefits of possible future global policies for managing polioviruses. Am J Public Health. 2008;98(7):1322–1330.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Pallansch MA, Cochi SL, et al. Economic analysis of the global polio eradication initiative. Vaccine. 2011;29(2):334–343.
   Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Pallansch MA, Cochi SL, et al. An economic analysis of poliovirus risk management policy options for 2013-2052. BMC Infect Dis. 2015;15(389). doi:https://doi.org/10.1186/s12879-015-1112-8
   Google Scholar
• Thompson KM, Duintjer Tebbens RJ. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes. BMC Infect Dis. 2015;15(374). doi:https://doi.org/10.1186/s12879-015-1113-7
   Google Scholar
• Duintjer Tebbens RJ, Thompson KM. Uncertainty and sensitivity analysis of cost assumptions for global long-term poliovirus risk management. J Vaccines Vacc. 2016;7(5):339.
   Google Scholar
• Duintjer Tebbens RJ, Thompson KM. Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential OPV cessation risk management strategy. Epidemiol Infect. 2017;145(2):217–226.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Thompson KM. The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management. Future Microbiol. 2016;11(12):1549–1561.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Thompson KM. Costs and benefits of including inactivated in addition to oral poliovirus vaccine in outbreak response after cessation of oral poliovirus vaccine use. Med Decis Making Policy & Practice. 2017;2(1):1–13.
   Google Scholar
• Tucker AW, Isaacs D, Burgess M. Cost-effectiveness of changing from live oral poliovirus vaccine to inactivated poliovirus vaccine in Australia. Aust N Z J Public Health. 2001;25(5):411–416.
   PubMed Web of Science ®Google Scholar
• Jenkins PC, Modlin JF. Decision analysis in planning for a polio outbreak in the United States. Pediatrics. 2006;118(2):611–618.
   PubMed Web of Science ®Google Scholar
• Chumakov K, Avidan MS, Benn CS, et al. Old vaccines for new infections: exploiting innate immunity to control COVID-19 and prevent future pandemics. Proc Natl Acad Sci U S A. 2021;118(21):e2101718118.
   PubMed Web of Science ®Google Scholar
• Shann F. Immunization–dramatic new evidence. P N G Med J. 2000;43(1–2):24–29.
   PubMedGoogle Scholar
• Byberg S, Fisker AB, Thysen SM et al, et al. Cost-effectiveness of providing measles vaccination to all children in Guinea-Bissau. Glob Health Action. 2017;10(1):1329968.
   PubMed Web of Science ®Google Scholar
• Thysen SM, Fisker AB, Byberg S et al, et al. Disregarding the restrictive vial-opening policy for BCG vaccine in Guinea-Bissau: impact and cost-effectiveness for tuberculosis mortality and all-cause mortality in children aged 0-4 years. BMJ Glob Health. 2021;6(8):e006127.
   PubMed Web of Science ®Google Scholar
• Arnal JM, Frisas O, Garuz R, et al. Cost effectiveness of hepatitis A virus immunisation in Spain. Pharmacoecon. 1997;12(3):361–373.
   PubMed Web of Science ®Google Scholar
• Chodick G, Lerman Y, Peled T et al, et al. Cost-benefit analysis of active vaccination campaigns against hepatitis A among daycare centre personnel in Israel. Pharmacoeconomics. 2001;19(3):281–291.
   PubMed Web of Science ®Google Scholar
• Dye C. Making wider use of the world’s most widely used vaccine: bacille Calmette-Guerin revaccination reconsidered. J R Soc Interface. 2013;10(87):20130365.
   PubMed Web of Science ®Google Scholar
• Waye A, Chuck AW, Jacobs P et al, et al. Prevnar 7 childhood immunization program and serotype replacement: changes in pneumococcal incidence and resulting impact on health care costs in Alberta (2003-2008). Drugs Real World Outcomes. 2015;2(2):153–161.
   PubMedGoogle Scholar
• Flasche S, Jit M, Rodríguez-Barraquer I, et al. The long-term safety, public health impact, and cost-effectiveness of routine vaccination with a recombinant, live-attenuated dengue vaccine (Dengvaxia): a model comparison study. PLoS Med. 2016;13(11):e1002181.
   PubMed Web of Science ®Google Scholar
• Sandmann F, Ramsay M, Edmunds WJ et al, et al. How to prevent vaccines falling victim to their own success: intertemporal dependency of incidence levels on indirect effects in economic reevaluations. Value Health. 2021;24(10):1391–1399.
   PubMed Web of Science ®Google Scholar
• Biggart R, Finn A, Marlow R. Lack of impact of rotavirus vaccination on childhood seizure hospitalizations in England - An interrupted time series analysis. Vaccine. 2018;36(31):4589–4592.
   PubMed Web of Science ®Google Scholar
• Duke T, Mgone CS. Measles: not just another viral exanthem. 2003;361(9359):763–773.
   Google Scholar
• Arnoux S, Weinberger C, Gessner BD. Vaccine-preventable influenza disease burden from clinical trials of Vaxigrip - an inactivated split virion influenza vaccine - supports wider vaccine use. Vaccine. 2007;25(45):7720–7731.
   PubMed Web of Science ®Google Scholar
• Jit M, Newall AT, Beutels P. Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies. Hum Vaccin Immunother. 2013;9(4):834–840.
   PubMed Web of Science ®Google Scholar
• Cooper WO, Boyce TG, Wright PF, et al. Do childhood vaccines have non-specific effects on mortality? Bull World Health Organ. 2003;81(11):821–826.
   PubMed Web of Science ®Google Scholar
• Mina MJ, Metcalf CJE, de Swart RL, et al. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. Science. 2015;348(6235):694–699.
   PubMed Web of Science ®Google Scholar
• Chumakov K, Benn CS, Aaby P, et al. Can existing live vaccines prevent COVID-19? Science. 2020;368(6496):1187.
   PubMed Web of Science ®Google Scholar
• Thompson KM. Good news for billions of children who will receive IPV. Lancet Infecti Dis. 2015;15(10):1120–1122
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Poliomyelitis prevention in the United States. Updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2000;49(RR–5):1–22.
   PubMedGoogle Scholar
• Gonzalez-Perez M, Sanchez-Tarjuelo R, Shor B, et al. The BCG vaccine for COVID-19: first verdict and future directions. Front Immunol. 2021;12:632478.
   PubMed Web of Science ®Google Scholar
• Uchida A, Yonou H, Hayashi E, et al. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis. Urology. 2007;69(2):275–279.
   PubMed Web of Science ®Google Scholar
• Bachir BG, Dragomir A, Aprikian AG, et al. Contemporary cost-effectiveness analysis comparing sequential bacillus Calmette-Guerin and electromotive mitomycin versus bacillus Calmette-Guerin alone for patients with high-risk non-muscle-invasive bladder cancer. Cancer. 2014;120(16):2424–2431.
   PubMed Web of Science ®Google Scholar
• Perry RT, Halsey NA. The clinical significance of measles: a review. J Infecti Dis. 2004;189(Supplement_1):S4–S16
   PubMed Web of Science ®Google Scholar
• Thompson KM, Odahowski CL. Systematic review of health economic analyses of measles and rubella immunization interventions. Risk Anal. 2016;36(7):1297–1314.
   PubMed Web of Science ®Google Scholar
• Aaby P, Bhuiya A, Nahar L et al, et al. The survival benefit of measles immunization may not be explained entirely by the prevention of measles disease: a community study from rural Bangladesh. Int J Epidemiol. 2003;32(1):106–116.
   PubMed Web of Science ®Google Scholar
• Agrawal B. Heterologous immunity: role in natural and vaccine-induced resistance to infections. Front Immunol. 2019;10:2631.
   PubMed Web of Science ®Google Scholar
• Marín-Hernández D, Nixon DF, Hupert N. Heterologous vaccine interventions: boosting immunity against future pandemics. Mol Med. 2021;27(1):54.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Graham JD. Going beyond the single number: using probabilistic risk assessment to improve risk management. Hum Ecol Risk Assess. 1996;2(4):1008–1034.
   Web of Science ®Google Scholar
• Shukla R, Ramasamy V, Shanmugam RK et al, et al. Antibody-dependent enhancement: a challenge for developing a safe dengue vaccine. Front Cell Infect Microbiol. 2020;10:572681.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Kalkowska DA. An updated economic analysis of the global polio eradication initiative. Risk Anal. 2021;41(2):393–406.
   PubMed Web of Science ®Google Scholar
• Bollaerts K, Verstraeten T, Cohet C. Observational studies of non-specific effects of Diphtheria-Tetanus-Pertussis vaccines in low-income countries: assessing the potential impact of study characteristics, bias and confounding through meta-regression. Vaccine. 2019;37(1):34–40.
   PubMed Web of Science ®Google Scholar
• Thompson KM. Is introduction of IPV “Good news for billions of children”?–Author’s reply. Lancet Infect Dis. 2016;16(4):410.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Kalkowsa DA, Badizadegan K. No role for reintroducing OPV into the United States with respect to controlling COVID-19 [Response to the letter to the editor by Chumakov et al.]. Risk Anal. 2021;41(2):389–392.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Kalkowska DA, Badizadegan K. Hypothetical emergence of poliovirus in 2020: part 1. Consequences of policy decisions to respond using nonpharmaceutical interventions. Expert Rev Vaccines. 2021;20(4):465–481.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Kalkowska DA, Badizadegan K. Hypothetical emergence of poliovirus in 2020: part 2. Exploration of the potential role of vaccines in control and eradication. Expert Rev Vaccines. 2021;20(4):449–460.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Duintjer Tebbens RJ. National choices related to inactivated poliovirus vaccine, innovation, and the end game of global polio eradication. Expert Rev Vaccines. 2014;13(2):221–234.
   PubMed Web of Science ®Google Scholar
• Badizadegan K, Vanlandingham DM, Hampton W et al, et al. Value of biopsy in a cohort of children with high-titer celiac serologies: observation of dynamic policy differences between Europe and North America. BMC Health Serv Res. 2020;20(1):962.
   PubMed Web of Science ®Google Scholar
• Ochalek J, Claxton K, Lomas J, et al. Valuing health outcomes: developing better defaults based on health opportunity costs. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):729–736.
   PubMed Web of Science ®Google Scholar
• Thomas T, Chandan JS, Li VSW et al, et al. Global smoking trends in inflammatory bowel disease: a systematic review of inception cohorts. PLOS ONE. 2019;14(9):e0221961.
   PubMed Web of Science ®Google Scholar
• Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384–413.
   PubMed Web of Science ®Google Scholar
• Hajjo R, Tropsha A. A systems biology workflow for drug and vaccine repurposing: identifying small-molecule BCG mimics to reduce or prevent COVID-19 mortality. Pharm Res. 2020;37(11):212.
   PubMed Web of Science ®Google Scholar
• Broniatowski DA, Jamison AM, Qi S, et al. Weaponized health communication: Twitter bots and Russian trolls amplify the vaccine debate. Am J Public Health. 2018;108(10):1378–1384.
   PubMed Web of Science ®Google Scholar
• Hotez PJ. Anti-science kills: from Soviet embrace of pseudoscience to accelerated attacks on US biomedicine. PLoS Biol. 2021;19(1):e3001068.
   PubMed Web of Science ®Google Scholar